Periportal thickening on magnetic resonance imaging for hepatic fibrosis in infantile cholestasis

Table 3 Diagnostic performance of the parameters

Variable	Cutoff value	Sensitivity (%)	Specificity (%)	AUC	95%CI	P value
Clinically significant fibrosis (F2-F4)
APRI	0.44	84.1	59.5	0.712	0.634-0.782	0.001
PT	4.2 mm	81.4	85.7	0.899	0.840-0.941	< 0.001
SR	0.85	85.0	54.8	0.741	0.664-0.808	< 0.001
Advanced fibrosis (F3-F4)
APRI	0.78	78.7	63.0	0.724	0.647-0.793	< 0.001
PT	5.3 mm	66.0	71.3	0.734	0.657-0.801	< 0.001
SR	1.1	61.7	78.7	0.742	0.666-0.809	< 0.001
Cirrhosis (F4)
APRI	1.24	90.0	70.3	0.715	0.637-0.785	0.002
PT	5.3 mm	70.0	62.1	0.656	0.675-0.730	0.058
SR	1.04	90.0	61.4	0.790	0.718-0.852	< 0.001

AUC: Area under the curve; APRI: Aspartate transaminase to platelet ratio index; PT: Periportal thickening; SR: Normalized spleen size ratio.